Draft of 17.3.2025

REGULATION

OF THE MINISTER FOR HEALTH[1)]

of …….. 2025

amending the Regulation on the list of psychotropic substances, narcotic drugs and new psychoactive substances[2)]

Pursuant to Article 44f of the Act of 29 July 2005 on the combating of drug addiction (Journal of Laws of 2023, item 1939), the following is hereby decreed:

§ 1. The Regulation of the Minister for Health of 17 August 2018 on the list of psychotropic substances, narcotic drugs and new psychoactive substances (Journal of Laws of 2024, item 1139) is hereby amended as follows:

1) In Annex 1 to this Regulation:

a) in Part ‘1. GROUP I-P PSYCHOTROPIC SUBSTANCES’ item 7 of the table is deleted;

b) in Part ‘2. GROUP II-P PSYCHOTROPIC SUBSTANCES’:

- item 76 of the table is replaced by the following:

76	α-PHiP	α-pyrrolidine-isohexanophenone, α-PiHP	4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one;

- the following items 79–82 are added:

79	3-CMC	3-chloromethcathinone, clophedrone	1-(3-chlorophenyl)-2-(methylamino)propan-1-one

[1])The Minister for Health manages the government health department pursuant to § 1(2) of the Regulation of the Prime Minister of 18 December 2023 concerning the specific scope of activities of the Minister for Health (Journal of Laws [Dziennik Ustaw], item 2704).

[2])This Regulation was notified to the European Commission on … under number …, pursuant to § 4 of the Cabinet Regulation of 23 December 2002 concerning the manner in which the national notification system of standards and legal acts functions (Journal of Laws, item 2039; and of 2004, item 597), which implements Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical standards and regulations and of rules on Information Society services (harmonisation) (OJ L 241, 17.9.2015, p. 1).

80	DIPENTYLONE	N,N-dimethylpentylone	1-(1,3-benzodioxol-5-yl)-2(dimethylamino)pentan-1-one
81	2-FDCK	2-fluorodeschloro-ketamine	2-(2-fluorophenyl)-2-(methylamino)cyclohexan-1-one
82	LISDEXAMFETAMINE		(2*S*)-2,6-diamino-N-[(2*S*)-1--phenylpropan-2-yl]hexanamide;

c) In part ‘4. GROUP IV-P PSYCHOTROPIC SUBSTANCES’, the following item 80 is added to the table:

80	BROMAZOLAM		8-bromo-6-phenyl-1-methyl-4*H*-[1,2,4]triazol[4,3-*a*][1,4]benzodiazepine;

2) in Annex 2 to the Regulation, in Part ‘1. GROUP I-N NARCOTIC DRUGS’,

a) item 115 of the table is replaced by the following:

115	LEVOMETHORPHAN*)		(-)-3-methoxy-17-methylmorphinan,

b) item 117 of the table is replaced by the following:

117	LEVORPHANOL*)		(-)-3-hydroxy-17-methylmorphinan,

c) the following item 211 is added to the table:

211	BUTONITAZENE		N,N-diethyl-2-[(4-butoxyphenyl)methyl]-5-nitro-1*H*-benzimidazole-1-ethanamine,

d) the following line is added at the end of the table:

*) Excluding the substances dextromethorphan ((+)-3-methoxy-17-methylmorphinan) and dextrorphan ((+)-3-hydroxy-17-methylmorphinan);

3) in Annex 3 to the Regulation:

a) in Part ‘1. List of new psychoactive substances with their names and chemical notations’,

- item 45 of the table is deleted;
- the following items 59–66 are added:

59	Δ^9-THCP	Δ^9-tetrahydrocannabiphorol	(6a*R*,10a*R*)-6a,7,8,10a-tetrahydro- -6,6,9-trimethyl-3-heptyl-6*H*- -dibenzo[*b*,*d*]piran-1-ol
60	HHCP	hexahydrocannabiphorol	6a,7,8,9,10,10a-hexahydro-6,6,9-trimetyl-3-heptyl-6*H*-dibenzo[*b*,*d*]piran-1-ol
61	GIDAZEPAM		2-(7-bromo-2-ox-5-phenyl-2,3-dihydro-1*H*-benzo[*e*][1,4]diazepin-1-yl)acetohydrazide
62	MDMB-5Br-INACA		methyl (2*S*)-2-[(5-bromo-1*H*-indazole-3-carbonyl)amino]-3,3-dimethylbutanoate
63	ADB-INACA		*N*-[1-(aminocarbonyl)-2,2- -dimethylpropyl]-1*H*-indazole-3-carboxamide
64	ADB-5Br-INACA		*N*-[1-(aminocarbonyl)-2,2-dimethylpropyl]-5-bromo-1*H*-indazole-3-carboxamide
65	IBOTENIC ACID		α-amino-3-hydroxy-5-isoxazoloacetic acid
66	MUSCIMOL		5-(aminomethyl)-3-hydroxy-isoxazole;

b) In part ‘4. Synthetic cannabinoids (cannabimimetics) — group III-NPS’:

- in item 4.1:

– – in the first sentence, the full stop is replaced by a comma and the words ‘1*H*-indole-2-on-1,3-diyl.’ are added;

– – the following letter (q) is added to the table:

q) 1*H*-indole-2-on-1,3-diyl (attached to the bridge at carbon 3 and to the side chain at nitrogen 1);	

– in item 4.2:

– – point (a) is replaced by the following:

‘a) a carbonyl, aza-carbonyl or methylenecarbonyl group (bonding to the basic structure occurs through the CH2 group carbon atom),’,

– – in point (d), the semicolon is replaced by a comma and the following point (e) is added:

‘(e) the carbonyl-hydrazone group (bonding to the basic structure occurs through the hydrazone group nitrogen atom connected by a double bond to position 3 of the basic group).’;

c) in Part ‘5. Fentanyl derivatives — group IV-NPS’ item 5.1(d) is replaced by the following:

d) R2 and R3 substituents can be a hydrogen atom or an alkyl (up to C6) or hydroxyl group.’;

d) the following Part 9 is added:

‘9. Benzimidazole derivatives — group VIII-NPS

Any compound derived from benzimidazole containing in its structure a basic structure with a maximum molecular weight of 500 u, in which atoms or groups of atoms may be substituted at positions Rn, R1, R2, R3 and R4, as described in item 9.1, and salts of these compounds, if the existence of such salts is possible.



BASIC STRUCTURE

In the basic structure:

1) the R1 and R2 substituents located at the nitrogen atom can be a hydrogen atom or an alkyl group (containing up to 3 carbon atoms, i.e. up to C3), with these substituents forming a cyclic system in which the nitrogen atom is contained in the pyrrolidinyl, piperidinyl and morpholinyl ring structure;

2) R3 and R4 substituents may be the atoms of: hydrogen, fluorine, chlorine, bromine, iodine, or alkyl (up to C3), nitro, trifluoromethyl, methoxyl, trifluoromethoxyl, cyan groups;
3) the Rn substituent located in any position (one or more) of the phenyl ring may be the following atoms: hydrogen, fluorine, chlorine, bromine, iodine, or alkyl (up to C6), alkoxyl (up to C5), trifluoromethoxyl, acetoxyl, alkylsulfanyl (up to C5), trifluoromethyl, hydroxyl, cyan groups.'.

§ 2. The Regulation shall enter into force 14 days after its publication.

THE MINISTER FOR HEALTH